8-L-Ornithinevasopressin Formulation Guide For Pharmaceutical Manufacturing
- Technical Stability: Requires pH control between 3.5 and 4.2 with nitrogen protection to prevent oxidation.
- Purity Standards: High-pressure liquid chromatography (HPLC) assay must confirm >98% peptide content.
- Supply Chain: Sourcing from a verified global manufacturer ensures consistent bulk price and COA reliability.
In the landscape of modern pharmaceutical manufacturing, the demand for high-purity vasoconstrictor agents remains critical for local anesthetic combinations and hemodynamic support. 8-L-Ornithinevasopressin, often recognized commercially as Ornipressin, serves as a potent Synthetic Vasopressin Analogue designed to minimize specific side effects associated with natural vasopressin while maintaining robust peripheral vasoconstriction. For formulation engineers and procurement specialists, understanding the chemical stability, excipient compatibility, and regulatory compliance of this Peptide Hormone is essential for successful scale-up.
As a premier global manufacturer, NINGBO INNO PHARMCHEM CO.,LTD. provides technical support and bulk supply chains dedicated to maintaining the integrity of sensitive peptide structures during production. This guide outlines the critical parameters for integrating this active pharmaceutical ingredient (API) into parenteral formulations.
Chemical Profile and Technical Specifications
The molecular structure of this compound involves a cyclic nonapeptide with a specific substitution at the eighth position. Unlike arginine vasopressin, the substitution modifies the pressor activity profile and metabolic stability. When evaluating Ornipressin Acetate for production, manufacturers must verify specific physical constants to ensure batch-to-batch consistency.
| Parameter | Specification | Test Method |
|---|---|---|
| CAS Registry Number | 3397-23-7 | N/A |
| Biological Activity | 260 - 330 Units/mg | Rat Pressor Assay |
| Appearance | White to Off-White Powder | Visual |
| Solubility | Soluble in Water and Dilute Acids | USP <659> |
| Storage Condition | 2-8°C, Protected from Light | Stability Study |
Technical data indicates that biological activity can vary based on the oxidation state of the cysteine residues. Therefore, sourcing materials with a verified Certificate of Analysis (COA) is non-negotiable. The activity range of 260 to 330 Units/mg is a standard performance benchmark for clinical efficacy. Deviations outside this range may indicate degradation during synthesis or improper storage conditions prior to formulation.
Formulation Compatibility and Stability
Developing a stable liquid or lyophilized dosage form requires careful attention to pH and oxidative stressors. Based on established manufacturing protocols, the optimal pH range for solution stability lies between 3.5 and 4.2. Deviations above pH 5.0 can accelerate deamination, while highly acidic conditions may promote hydrolysis of the peptide backbone.
Excipient Selection
To prevent oxidation of the sulfhydryl groups during storage, the inclusion of antioxidants is standard practice. Sodium bisulfite or cysteine hydrochloride is frequently employed. Furthermore, tonicity adjusters such as sodium chloride are required for parenteral administration. The following process flow represents a standard formulation guide for aseptic processing:
- Solvent Preparation: Use freshly distilled Water for Injection (WFI). Bubble with nitrogen gas for 20 minutes to remove dissolved oxygen.
- Drug Dissolution: Add the peptide hormone to approximately 80% of the final volume under nitrogen cover.
- pH Adjustment: Utilize dilute acetic acid or sodium hydroxide to adjust the solution to pH 3.5 - 4.2.
- Filtration: Pass the solution through a 0.22 µm sterilizing grade membrane filter.
- Filling: Aseptically fill into Type I glass ampoules or vials with nitrogen headspace flush.
For lyophilized products, bulking agents like mannitol or glycine are compatible. However, interaction studies must be conducted to ensure no adduct formation occurs during the freeze-drying cycle. Terminal sterilization at 116°C for 30 minutes is permissible for certain ampoule configurations, though aseptic filtration is preferred to preserve peptide integrity.
Quality Assurance and Regulatory Compliance
Compliance with international pharmacopoeia standards is mandatory for market approval. Manufacturers must adhere to a GMP standard that covers everything from raw material sourcing to final product release. Key quality control tests include:
- Identity: Confirmed via Mass Spectrometry (MS) and Amino Acid Analysis.
- Purity: Related substances assessed by HPLC, with individual impurities typically limited to <0.5%.
- Potency: Biological assay compared against a reference standard.
- Sterility: Membrane filtration method per pharmacopoeial requirements.
When evaluating suppliers, request a full COA that includes chromatograms and raw data for biological assays. An equivalent product from a different supplier must match not only the chemical specification but also the impurity profile to ensure regulatory interchangeability.
Strategic Sourcing and Supply Chain
Reliable access to high-purity peptides is a cornerstone of uninterrupted manufacturing. Supply chain volatility can impact bulk price and lead times. Partnering with a dedicated manufacturer mitigates these risks. NINGBO INNO PHARMCHEM CO.,LTD. offers scalable production capabilities designed to meet the rigorous demands of pharmaceutical clients seeking a drop-in replacement for existing supply lines.
For procurement teams evaluating vendors, technical support is as valuable as pricing. Understanding the synthesis pathway—such as the use of protecting groups like phthalyl derivatives during intermediate stages—provides insight into the manufacturer's capability to control impurities. When sourcing high-purity Ornipressin, buyers should prioritize suppliers who demonstrate transparency in their synthesis and purification processes.
Conclusion
The successful formulation of L-Ornithine Vasopressin derivatives requires a synergy of precise chemical engineering and robust quality systems. By maintaining strict control over pH, oxygen exposure, and temperature, manufacturers can ensure the therapeutic efficacy of the final product. Selecting a partner with proven technical expertise ensures that every batch meets the critical specifications required for patient safety and regulatory approval.